Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-13 DOI:10.1080/1750743X.2025.2517522

Stephanie S Cobelas-Cartagena, Emilio Amigo-Otero, Victoria García-Samblas, Jesus Flores-Raposo, Silvia Rodrigo-Herrero, Juan Bayo-Calero

引用次数: 0

Abstract

The use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of many malignancies. However, they may be associated with life-threatening immune-mediated adverse effects.In this article, we present the case of a patient diagnosed with stage IIB acral melanoma (pT4aN0M0) who started adjuvant treatment with pembrolizumab, after which he developed severe myocarditis with myositis and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod.The use of Efgartigimod resulted in a remarkable recovery, marking the first reported acute application of this agent for IM3OS and positive anti-acetylcholine receptor antibodies (anti-AChR).

查看原文本刊更多论文

埃夫加替莫德治疗派姆单抗诱导的心肌炎、肌炎和重症肌无力重叠综合征（IM3OS） 1例

免疫检查点抑制剂（ICIs）的使用彻底改变了许多恶性肿瘤的治疗。然而，它们可能与危及生命的免疫介导的不良反应有关。在这篇文章中，我们报告了一例被诊断为IIB期肢端黑色素瘤（pT4aN0M0）的患者，他开始使用派姆单抗进行辅助治疗，之后他患上了严重的心肌炎，并伴有肌炎和重症肌无力重叠综合征（IM3OS）。Efgartigimod的使用取得了显著的恢复，这是首次报道该药物急性应用于IM3OS和抗乙酰胆碱受体抗体阳性（抗achr）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.